BR112017000556A2 - terapia de combinação para câncer - Google Patents
terapia de combinação para câncerInfo
- Publication number
- BR112017000556A2 BR112017000556A2 BR112017000556A BR112017000556A BR112017000556A2 BR 112017000556 A2 BR112017000556 A2 BR 112017000556A2 BR 112017000556 A BR112017000556 A BR 112017000556A BR 112017000556 A BR112017000556 A BR 112017000556A BR 112017000556 A2 BR112017000556 A2 BR 112017000556A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- cancer combination
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462023748P | 2014-07-11 | 2014-07-11 | |
US201462033062P | 2014-08-04 | 2014-08-04 | |
US201462033566P | 2014-08-05 | 2014-08-05 | |
US201562149941P | 2015-04-20 | 2015-04-20 | |
US201562156928P | 2015-05-05 | 2015-05-05 | |
PCT/US2015/039939 WO2016007854A1 (en) | 2014-07-11 | 2015-07-10 | Combination therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017000556A2 true BR112017000556A2 (pt) | 2017-11-07 |
Family
ID=53682893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017000556A BR112017000556A2 (pt) | 2014-07-11 | 2015-07-10 | terapia de combinação para câncer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170128448A1 (pt) |
EP (1) | EP3166635A1 (pt) |
JP (1) | JP2017521396A (pt) |
KR (1) | KR20170029565A (pt) |
CN (1) | CN107073122A (pt) |
AU (1) | AU2015287694A1 (pt) |
BR (1) | BR112017000556A2 (pt) |
CA (1) | CA2954652A1 (pt) |
CL (1) | CL2017000050A1 (pt) |
EA (1) | EA201790164A1 (pt) |
HK (1) | HK1231381A1 (pt) |
IL (1) | IL249898A0 (pt) |
MX (1) | MX2017000366A (pt) |
SG (1) | SG11201700201UA (pt) |
WO (1) | WO2016007854A1 (pt) |
ZA (1) | ZA201608559B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE026827T2 (en) | 2006-09-26 | 2016-07-28 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
CA2829570C (en) | 2011-03-11 | 2019-05-07 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
JP2015531776A (ja) | 2012-09-04 | 2015-11-05 | セルジーン コーポレイション | 3−(5−アミノ−2−メチル−4−オキソキナゾリン−3(4h)−イル)ピペリジン−2,6−ジオンのアイソトポログ及びその製造方法 |
WO2017004532A1 (en) | 2015-07-02 | 2017-01-05 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
AU2016364753A1 (en) | 2015-12-02 | 2018-06-14 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione |
WO2019083866A1 (en) * | 2017-10-23 | 2019-05-02 | Atara Biotherapeutics, Inc. | METHODS FOR ADJUSTING IMMUNOTHERAPY MANAGEMENT TUMORAL FLOOD MANAGEMENT |
AU2019261986A1 (en) | 2018-05-03 | 2020-11-26 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (CAR) T cell therapy and a kinase inhibitor |
WO2021080937A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same |
AU2020369497A1 (en) | 2019-10-21 | 2022-05-19 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024108028A1 (en) * | 2022-11-16 | 2024-05-23 | Salarius Pharmaceuticals, Inc. | Methods of use of deuterium-enriched compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001227851A1 (en) * | 2000-01-12 | 2001-07-24 | Emag Technologies L.L.C. | Low cost compact omni-directional printed antenna |
US7346839B2 (en) * | 2003-09-30 | 2008-03-18 | Google Inc. | Information retrieval based on historical data |
US20060003059A1 (en) * | 2004-07-02 | 2006-01-05 | Burt Tabora | Combined preparation and apparatus for use with a food blender and method for making preparation |
TWI423039B (zh) * | 2010-07-23 | 2014-01-11 | Quanta Comp Inc | 伺服器系統與其操作方法 |
BR112013023277A2 (pt) * | 2011-03-11 | 2017-06-27 | Celgene Corp | métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona |
TW201521725A (zh) * | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
US20140314752A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
CA2909625C (en) * | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
WO2014179661A1 (en) * | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
-
2015
- 2015-07-10 BR BR112017000556A patent/BR112017000556A2/pt not_active IP Right Cessation
- 2015-07-10 KR KR1020177003385A patent/KR20170029565A/ko unknown
- 2015-07-10 MX MX2017000366A patent/MX2017000366A/es unknown
- 2015-07-10 US US15/323,173 patent/US20170128448A1/en not_active Abandoned
- 2015-07-10 WO PCT/US2015/039939 patent/WO2016007854A1/en active Application Filing
- 2015-07-10 EA EA201790164A patent/EA201790164A1/ru unknown
- 2015-07-10 CN CN201580037534.4A patent/CN107073122A/zh active Pending
- 2015-07-10 AU AU2015287694A patent/AU2015287694A1/en not_active Abandoned
- 2015-07-10 SG SG11201700201UA patent/SG11201700201UA/en unknown
- 2015-07-10 JP JP2016574049A patent/JP2017521396A/ja not_active Abandoned
- 2015-07-10 EP EP15739486.7A patent/EP3166635A1/en not_active Withdrawn
- 2015-07-10 CA CA2954652A patent/CA2954652A1/en not_active Abandoned
-
2016
- 2016-12-12 ZA ZA2016/08559A patent/ZA201608559B/en unknown
-
2017
- 2017-01-02 IL IL249898A patent/IL249898A0/en unknown
- 2017-01-09 CL CL2017000050A patent/CL2017000050A1/es unknown
- 2017-05-18 HK HK17105024.0A patent/HK1231381A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CL2017000050A1 (es) | 2017-08-11 |
IL249898A0 (en) | 2017-03-30 |
ZA201608559B (en) | 2018-04-25 |
HK1231381A1 (zh) | 2017-12-22 |
SG11201700201UA (en) | 2017-02-27 |
KR20170029565A (ko) | 2017-03-15 |
MX2017000366A (es) | 2017-04-27 |
CA2954652A1 (en) | 2016-01-14 |
AU2015287694A1 (en) | 2017-02-02 |
EA201790164A1 (ru) | 2017-10-31 |
EP3166635A1 (en) | 2017-05-17 |
US20170128448A1 (en) | 2017-05-11 |
JP2017521396A (ja) | 2017-08-03 |
CN107073122A (zh) | 2017-08-18 |
WO2016007854A1 (en) | 2016-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017000556A2 (pt) | terapia de combinação para câncer | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
PH12017502142A1 (en) | Tetrasubstituted aklene compounds and their use | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
PH12018502731A1 (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
PH12016502352A1 (en) | Pharmaceutical composition | |
SA515370011B1 (ar) | طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين | |
TW201613578A (en) | Pharmaceutical combinations | |
NZ722600A (en) | Methods of treating mild brain injury | |
CL2018001434A1 (es) | Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
MX2018004112A (es) | Terapia de combinacion racional para el tratamiento de cancer. | |
MX2018001528A (es) | Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña. | |
DOP2014000258A (es) | Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro | |
IN2014DE00822A (pt) | ||
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
IN2014DE00818A (pt) | ||
MX2015016893A (es) | Combinacion de ro5503781 y capecitabina para la terapia para el cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |